Gujarat Themis Biosyn Ltd

As of June 30, 2026, Gujarat Themis Biosyn Ltd carries a market capitalization of 43.24B, placing it among publicly traded companies globally. Its enterprise value stands at 43.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gujarat Themis Biosyn Ltd has 108.97M shares outstanding.

As of June 30, 2026, Gujarat Themis Biosyn Ltd trades at a trailing price-to-earnings ratio of 88.76.

As of June 30, 2026, Gujarat Themis Biosyn Ltd trades at an EV/EBITDA multiple of 52.47 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 24.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 64.01 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 43.24B versus a market cap of 43.24B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.63M in revenue per employee across its workforce of 375.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gujarat Themis Biosyn Ltd recorded 164.49M in income tax expense. That works out to an effective tax rate of 25.25, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 651.36M, leaving 486.87M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Gujarat Themis Biosyn Ltd's stock has declined approximately 22.44% over the past 52 weeks. The 50-day moving average sits at 394.22, while the 200-day moving average is 359.38.

Over the twelve months ended June 30, 2026, Gujarat Themis Biosyn Ltd generated 1.74B in revenue and converted that into 486.87M in net income, yielding earnings per share of 4.47. EBITDA reached 824.03M, while operating income came in at 675.44M.

Over the twelve months ended June 30, 2026, Gujarat Themis Biosyn Ltd posted a gross margin of 85.63, reflecting its pricing power and cost economics. The operating margin of 38.88 and net profit margin of 28.02 provide insight into operational efficiency.

Gujarat Themis Biosyn Ltd's most recent stock split took place on August 9, 2024 with a 2:3 split ratio.